

10/555860

JC20 Rec'd PCT/PTO 01 NOV 2005

Docket No.: 04279/100M213-US1  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

---

In re Patent Application of:  
Christopher P. Holmes et al.

Application No.: Not Yet Assigned

Confirmation No.: N/A

Filed: Concurrently Herewith

Art Unit: N/A

For: NOVEL SPACER MOIETY FOR POLY  
(ETHYLENE GLYCOL) MODIFIED  
PEPTIDE BASED COMPOUNDS

---

Examiner: Not Yet Assigned

**INFORMATION DISCLOSURE STATEMENT (IDS)**

MS PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith.

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

Application No.: Not Yet Assigned

2

Docket No.: 04279/100M213-US1

1020 Received 11 NOV 2005


In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Our check in the amount of \$1,130.00 covering the fee set forth in 37 CFR 1.492(a), 1.492(c)(2), 1.492(b)(3), 1.492(e), and 1.492(f) is enclosed. The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: November 1, 2005

Respectfully submitted,

By  (53,970)  
Jonathan M. Spenner, Ph.D.

Registration No.: 57,268  
DARBY & DARBY P.C.  
P.O. Box 5257  
New York, New York 10150-5257  
(212) 527-7700  
(212) 527-7701 (Fax)  
Attorneys/Agents For Applicant

JC20 Rec'd PEG/PTO 01 NOV 2005

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number <b>101555860</b>	
				Filing Date <b>Concurrently Herewith</b>	
				First Named Inventor <b>Christopher P. Holmes</b>	
				Art Unit <b>N/A</b>	
				Examiner Name <b>Not Yet Assigned</b>	
Sheet	1	of	1	Attorney Docket Number <b>04279/100M213-US1</b>	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AA*	US-4,179,337	12-18-1979	Davis et al.	
	AB*	US-6,113,906	09-08-2000	Greenwald, R.B. et al	
	AC*	US-20020015691-A1	02-07-2002	Greenwald et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	BA	WO-92/16555	10-01-1992	Enzion, Inc.		
	BB	WO-96/40772	12-19-1996	Johnson & Johnson		
	BC	WO-96/40750	12-19-1996	Glaxo Group Ltd.		
	BD	WO-96/40189	12-19-1996	Glaxo Group Ltd.		
	BE	WO-98/25965	06-18-1998	Glaxo Group Ltd.		
	BF	WO-00/24770	05-04-2000	Amgen, Inc.		
	BG	WO-00/24782	05-04-2000	Amgen, Inc.		
	BH	WO-00/33881	06-15-2000	Debio Rech Pharma S.A.		
	BI	WO-02/065988	08-29-2002	Enzion, Inc.		
	BJ	WO-2004/014424	02-19-2004	Enzion, Inc.		
	BK	WO-2004/101600	11-25-2004	Affymax, Inc.		
	BL	WO-2004/101606	11-25-2004	Affymax, Inc.		
	BM	WO-2004/101611	11-25-2004	Affymax, Inc.		
	BN	WO-2004/108070	12-16-2004	Enzion, Inc.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	Wrighton et al., "Increased Potency of an Erythropoietin Peptide Mimetic Through Covalent Dimerization." Nature Biotechnology, Nature Publishing, US, Vol. 15, (11-1-1997).	
	CB	Greenwald et al., "Effective drug delivery by PEGylated drug conjugates", Advanced Drug Delivery Reviews. Amsterdam, NL. Vol. 55, N. 2, Pages 217-250 (02-10-2003).	
	CC	Greenwald et al., "Controlled release of proteins from their poly(ethylene glycol) conjugates: Drg delivery systems employing 1,6-elimination." Bioconjugate Chemistry. Vol. 14, No. 2, Pages 395-403 (04-03-2003).	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--